Navigation Links
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Date:6/12/2013

n entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidate is preliminary and investigative. Such product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

CONTACT:


Amgen, Thousand Oaks

Ashleigh Koss, 805-313-6151 (media)

Arvind Sood, 805-447-1060 (investors)

 

MedImmune/AstraZeneca

Tracy Rossin, 301-398-1468 (media)

Karl Hard +44 20-7604-8123 (investors)

Colleen Proctor 302-886-1842 (investors)

Ed Seage 302-886-4065 (investors)

References

1Krueger, Gerald G., MD. Clinical Features of Psoriatic Arthritis. The American Journal of Managed Care. 2002; 8:160-170

2Krueger G, Koo J, Lebwohl M, et al. The Impact of Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol. 2001; 137:280-4 

3International Federation of Psoriasis Associations, Important facts about psoriasis http://www.ifpa-pso.org/web/page.aspx?refid=47

4About Psoriasis: Statistics. National Psoriasis Foundation. http://ww
'/>"/>


SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
(Date:8/20/2014)... Stimulating nerves in your ear could improve the health ... at the University of Leeds used a standard TENS ... apply electrical pulses to the tragus, the small raised ... front of the ear canal. , The stimulation changed ... by reducing the nervous signals that can drive failing ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... 9, 2012 , Collaboration to create ... to active TB, enabling early treatment and disease outbreak prevention ... infectious disease portfolio with development of DNA-/RNA-based test that complements ... , New assay will use whole blood transcription profiling ...
... a report published in Nature Physics , they used ... magnetic. Graphene is a sheet of carbon atoms ... it exhibits no signs of the conventional magnetism usually associated ... remarkable properties won Manchester researchers the Nobel Prize in Physics ...
... Bioscience announced today that it has secured $47.5 million ... in the financing along with existing investors OrbiMed Advisors, ... with the financing, Josh Bilenker, M.D., Partner at Aisling ... of this round will support commercialization of the company,s ...
Cached Biology Technology:QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 2QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 3QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 5QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 6QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 7Graphene reveals its magnetic personality 2Roka Bioscience Secures $47.5 Million in Series D Financing 2
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... use a previously unknown process for harvesting energy and ... a Penn State University scientist has discovered. The discovery ... plant growth, harvesting energy from the Sun, and understanding ... and other lakes worldwide. A paper describing the discovery ... edition of the journal Science on 21 ...
(Date:8/21/2014)... easy to ignore, but they are the ultimate source ... Humans are increasingly dependent on algae, too, to suck ... it to the bottom of the ocean. Now, by ... researchers have evidence showing that viruses infecting those algae ... even when all else stays essentially the same, and ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
... American Society for Microbiology (ASM) Raymond W. Sarber ... Harvard College, Cambridge, Massachusetts. This award recognizes students ... excellence and potential. Ms. Clapham, currently a ... in the laboratory of Richard Losick, where she ...
... be the first recipient of a prestigious award given by ... Meeting of the Ecological Society of America on August 3. ... an outstanding record of informing their political decision-making with ecological ... figure that has a sharp appreciation for local and global ...
... DCMay 28, 2008The inaugural 2008 American Society for ... is being presented to Mary Ann Moran, Distinguished ... Georgia, Athens. This award honors the late David ... scientific approach and for being a dedicated and ...
Cached Biology News:American Society for Microbiology honors Mary Ann Moran 2
...
Luminometers...
... serial preparation of four ... cytosol/particulate/cytoskeleton/nuclear fractions from one ... can directly be used ... as 2-D gel/Western blot/gel-shift/translocation/enzyme ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Biology Products: